Takeda today announced positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune…
Sanofi is set to present new data from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), occurring from June 22-26, 2024, in…
Today, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI® (adagrasib) in combination with cetuximab. This targeted treatment is for adult…
Bristol Myers Squibb announced today that the European Medicines Agency (EMA) has validated its application to introduce a new subcutaneous administration route for Opdivo® (nivolumab). This includes a new pharmaceutical…
Audrey Duval Derveloy Appointed Global Head of Corporate Affairs at Sanofi Audrey Duval Derveloy, a seasoned leader in the healthcare industry and current President of Sanofi France, has been appointed…
Eli Lilly and Company (NYSE: LLY) has released detailed results from the SURMOUNT-OSA phase 3 clinical trials, which evaluated tirzepatide injections (10 mg or 15 mg) for treating moderate-to-severe obstructive…
Sanofi and Biovac, based in Cape Town, South Africa, have announced a significant partnership aimed at local manufacturing of inactivated polio vaccines (IPV) across Africa. This collaboration marks a milestone…
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast…
Roche announced today the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the…
FDA Approves SKYRIZI® for Ulcerative Colitis, Expanding AbbVie’s IBD Portfolio AbbVie announced that the U.S. FDA has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis. This…
Lilly’s Commitment to Safe Use of Mounjaro® and Zepbound® Lilly is dedicated to improving lives for people with diabetes and obesity through innovative medications like Mounjaro® and Zepbound®. Guided by…
Actylis, a prominent global manufacturer and sourcing expert specializing in critical materials and performance ingredients for life sciences and specialty chemicals, has appointed Scott Thomson as its new Chief Executive…